Company Profile

NeuroSystec Corporation
Profile last edited on: 6/6/19      CAGE: 47XW3      UEI:

Business Identifier: Delivery of neurologically active drugs via ultraminiature implantable devices
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

25134 Rye Canyon Loop
Santa Clarita, CA 91355
   (661) 702-6776
Location: Single
Congr. District: 25
County: Los Angeles

Public Profile

NeuroSystec Corporation had been structured around development of fully implanted drug delivery devices specifically for delivering drugs to the ear to treat tinnitus. Chairman of the board was the late Alfred E Mann who over his lifetime had started several medical device companies pioneering the development of pacemakers for erratic hearts, insulin pumps for diabetics, cochlear implants for the deaf and retinal implants for the blind. He died at the age of 90. His death was announced by one of his companies, MannKind Corporation in which he had been actively involved until only days before his death when he abruptly stepped down as chairman. In 2013 it was announced that Otonomy - a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear - had completed the acquisition of certain assets and rights to intellectual property (IP) related to the use of gacyclidine for the treatment of tinnitus from an affiliate of NeuroSystec Corporation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $952,567
Project Title: Nanoparticle Formulation of a Drug for Direct Inner Ear Therapy

Key People / Management

  Thomas J Lobl -- Vice President of Research and Development

  John V Schloss